Onco Actu du 25 mai 2016

	1. Biologie
New Stanford-developed Tool Allows Easier Study Of Blood Cancers [Scope Blog] Researchers in the laboratory of Stanford’s Ravi Majeti, MD, PhD, have just created one such tool — a method of implanting cells to create a human bone-like structure in mice. This allows investigators to study a whole host of blood cancers and other diseases that they had trouble studying before.
MD Anderson study uncovers early genetic changes in premalignant colorectal tissue [MD Anderson] Findings point to drivers of early cancer development, targets for cancer prevention therapies.
	3.1 Tabac
Drop in rate of adult smokers hits 20-year high [STAT] The rate of smoking among adults in the United States fell to 15 percent last year thanks to the biggest one-year decline in more than 20 years, according to a new government report.
	3.1.1 Tabac - e-cigs
E-cigarettes are still 'a bet' and diseases may emerge within 10 or 20 years, warns Imperial College  [The Telegraph] The research, published in the journal Tobacco Control, used data from over 53,000 people across Europe and showed that France had the highest use of e-cigarettes - with one in five people saying they had tried the devices.
E-cigarette use rose rapidly in UK, France: European study [Reuters] The research, led by scientists at Britain's Imperial College London, looked at attitudes to and use of e-cigarettes across Europe between 2012 and 2014. It found that France had the highest use of e-cigarettes, with the proportion of those who had tried one nearly tripling to 21.3 percent from 7.3 percent.
	5.2 Pharma
Pfizer cancer chief touts up-and-coming portfolio, sees pricing advantage on immunotherapies [FiercePharma] Pfizer also has a laundry list of other potential combos, which brought up a question from UBS analyst Marc Goodman: What about pricing? If each drug costs, say, $100,000, then would three together in a cocktail cost $300,000? “Absolutely no,” Barrett said.
	5.2.1 Pharma - Partenariats
MorphoSys, MD Anderson join forces to develop novel oncology therapeutics [MD Anderson] MorphoSys will apply its proprietary Ylanthia technology to generate and optimize fully human antibody candidates against jointly selected targets. The parties will collaborate in target validation and preclinical drug development to quickly bring selected candidates into the clinic.
	5.2.2 Pharma - Fusions & Acquisitions
Exclusive: Sanofi to unveil challenge to Medivation's board - sources [Reuters] Sanofi has threatened to oust the board after Medivation rejected its unsolicited $9.3 billion acquisition offer late last month, taking advantage of a so-called 'written consent' rule that gives Medivation shareholders the ability to act at any time to replace directors.
	5.3 Traitements - FDA, EMA,...
EMA to hold major review after fatal French trial [FierceBiotech] The European Medicines Agency is to undertake a large-scale review of trial practices alongside the French drugs agency as a result of the recent disastrous trial in France which saw a study participant die. This will form the basis of a wider public consultation on the possible changes to how early-stage studies are undertaken.
	6.1 Observation
More Men With Early Prostate Cancer Choosing to Avoid Treatment [NY Times] “Things are changing very, very quickly,” said Dr. Matthew R. Cooperberg, a urologist and epidemiologist at the University of California, San Francisco, who has been helping collect data for the new American Urological Association database.
	6.10 Politiques
Next step for Biden cancer effort: national summit in June [STAT] The summit, to take place in Washington on June 29, will bring together researchers, cancer survivors, patient advocates, federal agency officials, data and technology experts, oncologists and philanthropists in an attempt to add momentum to Biden’s initiative.